In the present work, Microspheres of Sumatriptan Succinate using PLGA, Ethyl cellulose and HPMC K4M as polymers were formulated to deliver Sumatriptan Succinate via oral route. The results of this investigation indicate that solvent evaporation method can be successfully employed to fabricate Sumatriptan Succinate microspheres. In this work an effort was made to formulate microsphere of Sumatriptan Succinate by using different polymers. Prepared formulations are evaluated for bulk density, tapped density, precent mucoadhesion, Percent compressibility, hausners ration, percentage yield, size and interaction study by Differential scanning calorimeter and in vitro drug release. Formulation which passed all the evaluation parameters was considered as best formulation of Sumatriptan Succinate. The present study conclusively that Sumatriptan Succinate microsphere could be prepared successfully and formulation F5 was shows satisfactory result.

A new, simple, precise, rapid, selective and stability reversed-phase high performance liquid chromatographic (RP-HPLC) method has been developed and validated for the simultaneous quantification of Perphenazine and Amitriptyline in pure form and its pharmaceutical dosage form. The method is based on Phenomenex Gemini C18 (4.6×250mm) 5µ column. The separation is achieved using isocratic elution by Methanol: TEA Buffer in the ratio of 65:35% v/v, pumped at flow rate 1.0mL/min and UV detection at 230nm. The column is maintained at 40°C throughout the analysis. The total run time is about 6min. The method is validated for specificity, accuracy, precision and linearity, robustness and ruggedness, system suitability, limit of detection and limit of quantitation as per International conference of harmonization (ICH) Guidelines. The method is accurate and linear for quantification of Perphenazine, Amitriptyline between 10 - 50µg/mL and 20 - 100µg/mL respectively. Further, satisfactory results are also established in terms of mean percent- age recovery (100.37% for Perphenazine and 100.34% for Amitriptyline, intra-day and inter-day precision (<2%) and robustness. The advantages of this method are good resolution with sharper peaks and sufficient precision. The results indicate that the method is suitable for the routine quality control testing of marketed tablet formulations.

A rapid and precise reverse phase high performance liquid chromatographic method has been developed for the validated of Cytarabine and Daunorubicin, in its pure form as well as in pharmaceutical dosage form. Chromatography was carried out on an Altima C18 (4.6mm x 150mm, 5µm) column using a mixture of ACN, Methanol and Phosphate buffer pH-4.6 (10:25:65 v/v) as the mobile phase at a flow rate of 1.0ml/min, the detection was carried out at 265nm. The retention time of the Cytarabine and Daunorubicin was 2.088, 6.068±0.02 min respectively. The method produces linear responses in the concentration range of 10-50mg/ml of Cytarabine and 20-100mg/ml of Daunorubicin. The method precision for the determination of assay was below 2.0%RSD. The method is useful in the quality control of bulk and pharmaceutical formulations.

In the present research work, we have designed a pulsatile formulation of Bosentan to treat High blood pressure as per the chronotherapeutic pattern of the disease. Core tablets were prepared by incorporating different concentration of disintegrants and were compressed in between different concentration of polymers. The core and compression coated tablets were subjected to pre-formulation, physicochemical and In-vitro drug release studies. FTIR studies revealed that there was not any chemical reaction between pure drug Bosentan and polymers. The pre and post-compressional parameters of tablets were also found to be within limits. Our optimized formulation F-6 releases Bosentan after a lag time of 2 hours and 98.01 % up to 12 hours. Formulations were stable for at least 3 months under standard long-term and accelerated storage conditions.

Niosomes are the non-ionic surfactant vesicles obtained on hydration of synthetic non-ionic surfactants. These are the promising vehicles for effective transdermal drug delivery. The present research work was aimed to develop niosomal-based transdermal Clozapine patch containing a stable formulation with improved drug permeation. Niosomes were prepared by solvent casting method. All the formulations were evaluated for vesicle size, zeta potential and percent entrapment efficiency. All the patches were then characterized for thickness, folding endurance, drug content determination, Flatness, and in vitro permeation studies. F3 formulation having optimum vesicle size (2.6m), highest zeta potential (-32.56mV) and maximum percent entrapment efficiency (98.09%) was selected as optimized formulation. The transdermal patch was prepared using solvent casting method from the optimised niosomes formulation F3 formulation. The prepared optimised niosomes F3 formulation were loaded into the patch formulation. Patches loaded with niosomes (F3NT3) showed 95.78 % cumulative amount of drug permeated. The optimized formulation (F3NT3) followed first order release kinetics.